Vaxon Biotech is focused on developing innovative immuno-therapeutic products aimed at treating various types of cancer through the use of therapeutic vaccines. Their primary technology involves the use of optimized cryptic peptides, which are designed to stimulate the immune system to recognize and attack cancer cells while sparing normal cells. This approach targets universal tumor antigens that are significantly overexpressed in tumors but present in minimal quantities in healthy tissues. Vaxon’s pipeline includes vaccines for major cancers such as lung, gastric, prostate, breast, renal, liver, and colorectal cancers, with a particular emphasis on addressing non-small-cell lung cancer (NSCLC) through their lead product, Vx-001.

Vx-001 has shown promising results in clinical trials, notably a Phase IIb study that demonstrated a significant increase in overall survival for never- and light-smokers with NSCLC compared to placebo. This vaccine has been recognized for its potential, receiving orphan medicinal product designation from both the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA). Vaxon Biotech's commitment to advancing cancer treatment through its proprietary technologies positions it as a key player in the field of cancer immunotherapy.

France

VAXON Biotechis a private company, located in Paris – France, that was founded in 2004. The company develops innovative therapeutic vaccines for the treatment of cancers including lung, gastric, prostate, breast, renal, liver and colorectal cancers, using itsproprietary technology of optimized cryptic peptides.

Vaxon Biotech

Company Details